BriaCell Therapeutics Corp. (NASDAQ:BCTX) Short Interest Down 30.7% in December

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the target of a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 1,650,000 shares, a drop of 30.7% from the December 15th total of 2,380,000 shares. Approximately 4.2% of the shares of the company are short sold. Based on an average trading volume of 1,540,000 shares, the short-interest ratio is presently 1.1 days.

Institutional Trading of BriaCell Therapeutics

A hedge fund recently bought a new stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. bought a new position in BriaCell Therapeutics Corp. (NASDAQ:BCTX) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics at the end of the most recent reporting period. 15.42% of the stock is currently owned by institutional investors.

BriaCell Therapeutics Price Performance

Shares of NASDAQ BCTX traded up $0.01 during midday trading on Wednesday, hitting $0.40. 876,955 shares of the company’s stock were exchanged, compared to its average volume of 1,261,475. BriaCell Therapeutics has a twelve month low of $0.38 and a twelve month high of $4.61. The firm has a market cap of $17.68 million, a P/E ratio of -0.34 and a beta of 1.55. The stock’s 50 day moving average price is $0.68 and its 200-day moving average price is $0.75.

BriaCell Therapeutics shares are set to reverse split on Wednesday, January 29th. The 1-15 reverse split was announced on Friday, January 3rd. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, January 28th.

BriaCell Therapeutics (NASDAQ:BCTX) last issued its quarterly earnings data on Monday, December 16th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). On average, analysts expect that BriaCell Therapeutics will post -1.01 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of BriaCell Therapeutics in a research report on Thursday, December 12th.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.